



Gufic Biosciences launches India's first indigenous Botulinum Toxin injection Zarbot

30 December 2022 | News

Developed and manufactured in collaboration with US-based Prime Bio

Mumbai-based Gufic Biosciences has launched indigenously produced 'Zarbot' (Botulinum Toxin Type A) injection in India.

'Zarbot' was unveiled by Dr Dirk Dressler, Dr Balaram Singh and several other prominent healthcare practitioners of India in a well-attended event held in Mumbai recently. 'Zarbot' has been developed and manufactured in collaboration with US-based Prime Bio.

One of the most important USPs of Zarbot is that it has been manufactured using purified HALL strain and proprietary technology which results in thin film formulation and better stability compared to other botulinum toxin brands.

Zarbot is an effective option for treating certain neurological conditions which can be more challenging with conventional therapy. It comes in a unique pack with 10 ml normal saline to improve compliance and can be stored at 2-8 °C for 36 months or 25 °C for 6 months before reconstitution and is also stable up to 14 days at 2-8 °C after reconstitution and multiple withdrawal of injection solution from vial under aseptic precautions.

The event thronged by the key opinion leaders from across the globe also witnessed the launch of the first state-of-the-art Centre of Excellence for Botulinum Toxin in India by Gufic. Currently only limited healthcare practitioners in India are well versed in injection technique of Botulinum Toxin. In this backdrop the Centre of Excellence launched by Gufic will offer training to healthcare practitioners on techniques of delivering complex injectable products like Botulinum Toxin.